Biomedical Engineering Reference
In-Depth Information
68. Wheeler, P.S., and Scott W.W., Jr. 1994. Medical devices and their radiologic vis-
ibility. In
Radiologic Guide to Medical Devices and Foreign Bodies
, T.B. Hunter and
D.G. Bragg, eds. Waltham, MA: Elsevier.
69. National Nanotechnology Initiative website http://www.nano.gov/html/
facts/whatIsNano.html (accessed December 2010).
70. Rocco, M. Nanotechnology Research Directions for Societal Need in 2020.
Report. Available at http://www.wtec.org/nano2/Nanotechnology Research_
Directions_to_2020/Nano_Research_Directions_to_2020pdf.
71. Vauthier, C. and Couvreur, P. 2007. Nanomedicines: A new approach for the
treatment of serious diseases.
Journal of Biomedical Nanotechnology
3: 1-12.
72. Helland, A., et al. 2007. Reviewing the environmental and human health knowl-
edge base of carbon nanotubes.
Environ Health Perspect
115: 1125-1131.
73. Rosen, Y., and Elman, N. 2009. Carbon nanotubes in drug delivery: Focus on
infectious disease.
Expert Opin Drug Del
6(5): 517-530.
74. Bawa, R. 2008. Nanoparticle-based therapeutics in humans: A survey.
Nanotechnology Law and Business
5(2): 135-155.
75. Oberdoster, G., Oberdoster, E. and Oberdoster, J. 2005. Nanotoxicology: An
emerging discipline evolving from studies of ultrafine particles.
Environ Health
Perspect
113: 823-839.
76. Bennett Woods, D. 2008.
Nanotechnology: Ethics and Society
. Boca Raton, FL: CRC
Press.
77. Nanotechnology: A report of the Food and Drug Administration Nanotechnology
Task Force 2007. Available at http://www.fda.gov/Science Research/Special
Topics/Nanotechnology/Nanotechnology Task Force/default.html.
78. Code of Federal Regulations website http://www.gpoaccess.gov/cfr/.
79. Drobovolskaia, M.A., and McNeil, S.S. 2007. Immunological properties of
nanoscale materials.
Nat. Nanotechnol.
2: 469-478.
80. Woodrow Wilson Center. Project on Emerging Nanotechnologies website
http://www.nanotechproject.org/ (Accessed December 2010).
81. Center for Disease Control and Prevention website http://www.cdc.gov.
82. Beatty, M.N., and Blumenthal, P.D. 2009. The levonorgestrel-releasing intrauter-
ine system: Safety, efficacy and patient acceptability.
Therapeutics and Clinical
Risk Management
5: 561-574.
83. Irving. S. 1993. Another look at the Dalkon Shield: Meta-analysis underscores its
problems.
Contraception
48(1): 1-12.
84. Tatum, H.J., Schmidt M.A., and Philips, D.M. Morphological studies of Dalkon
Shield tails removed from patients.
Contraception
11(4): 465-477.
85. Tanne, J.H. 2006. FDA approves silicone breast implants 14 years after their
withdrawal.
BMJ
333: 1139.
86. Krumholz, H., et al. 2007. What have we learnt from Vioxx?
BMJ
334: 120-123.
87. Finkelstein, J.B. 2008. Members of new FDA Board tied to industry.
JNCI
100(5):
296-297.
88. Deyo, R.A. 2004. Gaps, tensions and conflicts in the FDA approval process:
Implications for clinical practice.
J Am Board Fam Pract
17(2): 142-149.
89. Avorn, J. 2007. Keeping science on top of drug evaluation.
NEJM
357(7): 633-635.
90. Critical Path Initiative website http://www.fda.gov/ScienceResearch/
specialtopics/criticalpathinitiative.
Search WWH ::
Custom Search